{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+regimen&page=22", "query": { "intervention": "Control regimen", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 1565, "total_pages": 157, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+regimen&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+regimen&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T10:25:44.505Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01494987", "title": "Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Ranolazine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" }, { "name": "Diet", "type": "BEHAVIORAL" }, { "name": "Exercise", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 431, "start_date": "2012-01", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2014-11-18", "last_synced_at": "2026-10-30T10:25:44.505Z", "location_count": 46, "location_summary": "Mesa, Arizona • Tucson, Arizona • Pine Bluff, Arkansas + 39 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01494987" }, { "nct_id": "NCT07060014", "title": "NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Small Intestine Cancer", "Appendiceal Cancers" ], "interventions": [ { "name": "Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2026-09-18", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-30T10:25:44.505Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07060014" }, { "nct_id": "NCT02367833", "title": "Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Bone; Disorder, Development and Growth" ], "interventions": [ { "name": "Combined Oral Contraceptive", "type": "DRUG" }, { "name": "Transdermal Contraceptive", "type": "DRUG" }, { "name": "Contraceptive Vaginal Ring", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Penn State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "30 Years", "sex": "FEMALE", "summary": "18 Years to 30 Years · Female only" }, "enrollment_count": 60, "start_date": "2015-01", "completion_date": "2018-12", "has_results": true, "last_update_posted_date": "2020-03-09", "last_synced_at": "2026-10-30T10:25:44.505Z", "location_count": 1, "location_summary": "University Park, Pennsylvania", "locations": [ { "city": "University Park", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02367833" }, { "nct_id": "NCT04740567", "title": "Early Cognitive Intervention in Delirium", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Delirium", "Cognitive Decline", "Dementia" ], "interventions": [ { "name": "Cognitive Training", "type": "BEHAVIORAL" }, { "name": "Goal Management Training", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 283, "start_date": "2021-02-09", "completion_date": "2024-11-14", "has_results": true, "last_update_posted_date": "2025-12-24", "last_synced_at": "2026-10-30T10:25:44.505Z", "location_count": 2, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04740567" }, { "nct_id": "NCT03752307", "title": "Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Isoxsuprine Hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Corticosteroid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 2, "start_date": "2019-02-15", "completion_date": "2023-07-06", "has_results": true, "last_update_posted_date": "2024-02-06", "last_synced_at": "2026-10-30T10:25:44.505Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT03752307" }, { "nct_id": "NCT07322406", "title": "Kaempferol Absorption and Pharmacokinetics Evaluation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "No Disease", "Mitochondria Health", "Longevity", "Pharmacokinetics and Biological Absorption of Kaempferol in Healthy Adult", "Healthy Volunteers" ], "interventions": [ { "name": "Kaempferol", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 120, "start_date": "2025-12-09", "completion_date": "2027-12-22", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-10-30T10:25:44.505Z", "location_count": 3, "location_summary": "New York, New York • Chapel Hill, North Carolina • Pittsburgh, Pennsylvania", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07322406" }, { "nct_id": "NCT03430544", "title": "Cariprazine Effects on Brain and Behavior in Cocaine Use Disorder", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cocaine Use Disorder" ], "interventions": [ { "name": "Cariprazine Oral Capsule [Vraylar]", "type": "DRUG" }, { "name": "Placebo oral capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anna Rose Childress, Ph.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 14, "start_date": "2018-04-04", "completion_date": "2020-09-04", "has_results": false, "last_update_posted_date": "2020-09-09", "last_synced_at": "2026-10-30T10:25:44.505Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03430544" }, { "nct_id": "NCT06491030", "title": "Post-Operative Thoracolumosacral Orthosis for PJK", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Proximal Junctional Kyphosis", "Adult Spinal Deformity Surgery", "Thoracolumbosacral Orthosis" ], "interventions": [ { "name": "Align PJK™ TLSO brace", "type": "DEVICE" }, { "name": "Standard of Care", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "Hospital for Special Surgery, New York", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "30 Years to 75 Years" }, "enrollment_count": 84, "start_date": "2024-12-02", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-30T10:25:44.505Z", "location_count": 6, "location_summary": "Carmel, Indiana • Overland Park, Kansas • New York, New York + 3 more", "locations": [ { "city": "Carmel", "state": "Indiana" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "New York", "state": "New York" }, { "city": "Bellaire", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06491030" }, { "nct_id": "NCT04786093", "title": "Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Stereotactic radiation therapy", "type": "RADIATION" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-07-27", "completion_date": "2022-06-09", "has_results": true, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-30T10:25:44.505Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04786093" }, { "nct_id": "NCT06745908", "title": "Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "NSCLC Stage IV" ], "interventions": [ { "name": "N-803", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Prior failed checkpoint inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 507, "start_date": "2025-10-01", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-30T10:25:44.505Z", "location_count": 19, "location_summary": "Springdale, Arkansas • El Segundo, California • Fountain Valley, California + 14 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "El Segundo", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06745908" } ] }